Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland

Rouvio, Ory; Dvorkin, Tatyana; Amir-Kroll, Hila; Atias, Danit; Cohen, Irun R.; Rager-Zisman, Bracha; Porgador, Angel

doi:10.1016/j.vaccine.2005.02.002

Cited by 13 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Defined multi-component vaccines conjugated to peptide p458 were found to induce IgG antibodies to otherwise poorly immunogenic capsular polysaccharide antigens of salmonella [94], pneumococci [27,95], and meningococci [96]; these vaccines were found to be effective even without added adjuvants. The HSP60 peptide was also able to enhance the immunogenicity of peptides from viruses such as cytomegalovirus [97] and West Nile virus [98]. Thus, HSP60 functions as the body's natural adjuvant [26], probably as a result of its ability to activate the innate and the adaptive immune response.…”

Section: Discussionmentioning

confidence: 99%

The HSP60 immune system network

Quintana

Cohen

2011

Trends in Immunology

Self Cite

179

160

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The HSP60 immune system network

Quintana

Cohen

2011

Trends in Immunology

Self Cite

179

160

View full text Add to dashboard Cite

“…It is a natural ligand for TLR2 and TLR4 and, depending on its concentration, can act as a pro- or an anti-inflammatory mediator. Furthermore, it has previously been found to enhance immune response to peptides from West Nile virus [80] and cytomegalovirus [81]. It is currently unknown if TUDCA and 4-PBA could be used as effective adjuvants; however, their involvement in leptin sensitivity and immune function (TUDCA only), as well as the efficacy of other chaperones (i.e., HSP60) as vaccine adjuvants, make them promising candidates.…”

Section: Potential Adipokine-based Therapeutic Strategiesmentioning

confidence: 99%

Leptin-based adjuvants: An innovative approach to improve vaccine response

White

Taylor

Hurt

et al. 2013

Vaccine

View full text Add to dashboard Cite

Leptin is a pleiotropic hormone with multiple direct and regulatory immune functions. Leptin deficiency or resistance hinders the immunologic, metabolic, and neuroendocrinologic processes necessary to thwart infections and their associated complications, and to possibly protect against infectious diseases following vaccination. Circulating leptin levels are proportional to body fat mass. High circulating leptin concentrations, as observed in obesity, are indicative of the development of leptin transport saturation/signaling desensitization. Leptin bridges nutritional status and immunity. Although its role in vaccine response is currently unknown, over-nutrition has been shown to suppress vaccine-induced immune responses. For instance, obesity (BMI ≥ 30 kg/m2) is associated with lower antigen-specific antibody titers following influenza, hepatitis B, and tetanus vaccinations. This suggests that obesity, and possibly saturable leptin levels, are contributing factors to poor vaccine immunogenicity. While leptin-based therapies have not been investigated as vaccine adjuvants thus far, leptin’s role in immunity suggests that application of these therapies is promising and worth investigation to enhance vaccine response in people with leptin signaling impairments. This review will examine the possibility of using leptin as a vaccine adjuvant by: briefly reviewing the distribution and signal transduction of leptin and its receptors; discussing the physiology of leptin with emphasis on its immune functions; reviewing the causes of attenuation of leptin signaling; and finally, providing plausible inferences for the innovative use of leptin-based pharmacotherapies as vaccine adjuvants.

show abstract

“…The human immune system has a natural autoimmunity towards HSP, particularly HSP60 here, whereby CD4 + T-cells responses would be generated. HSP60 showed positive preclinical results in multiple occasions as an adjuvant which will provide help towards both CD8 + T-cells and B-cells due to activation of the CD4 + T helper cell in diseases such as murine CMV [85], Meningitides [87], and West Nile virus [88]. Therefore, with the right selection of M. tb antigen or attenuated whole M. tb cell in combination with potent adjuvant and the right pretreatment, we think that generation of a new line of vaccine for TB would not be a far cry away in the hope of eliminating TB.…”

Section: Future Directions Into Tb Vaccinesmentioning

confidence: 99%

Vaccines for TB: Lessons from the Past Translating into Future Potentials

Tye

Lew

Choong

et al. 2015

Journal of Immunology Research

View full text Add to dashboard Cite

Development of vaccines for infectious diseases has come a long way with recent advancements in adjuvant developments and discovery of new antigens that are capable of eliciting strong immunological responses for sterile eradication of disease. Tuberculosis (TB) that kills nearly 2 million of the population every year is also one of the highlights of the recent developments. The availability or not of diagnostic methods for infection has implications for the control of the disease by the health systems but is not related to the immune surveillance, a phenomenon derived from the interaction between the bacteria and their host. Here, we will review the immunology of TB and current vaccine candidates for TB. Current strategies of developing new vaccines against TB will also be reviewed in order to further discuss new insights into immunotherapeutic approaches involving adjuvant and antigens combinations that might be of potential for the control of TB.

show abstract

Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland

Cited by 13 publications

References 40 publications

The HSP60 immune system network

The HSP60 immune system network

Leptin-based adjuvants: An innovative approach to improve vaccine response

Vaccines for TB: Lessons from the Past Translating into Future Potentials

Contact Info

Product

Resources

About